# Determinants of Survival and Prognostic Factors in Patients Undergoing Liver Resection for Primary Hepatic Carcinoma—A Follow-Up Study

**Authors:** Unenbat Gurbadam, Gantuya Dorj, Aryabilig Otgongerel, Munkhtsetseg Janlav, Serod Khuyagaa, Tsenguun Ganbat, Tserendorj Demchig, Amgalantuul Batdelger, Batsaikhan Bayartugs, Munkhdelger Byambaragchaa, Yerbolat Amankeldi, Munkhzaya Chogsom, Chinburen Jigjidsuren, Bayart-Uils Bayar, Lkham Nyam-Osor

PMC · DOI: 10.3390/clinpract15070121 · 2025-06-26

## TL;DR

This study identifies factors affecting survival in patients who undergo liver surgery for liver cancer in Mongolia, emphasizing early detection and treatment.

## Contribution

The study provides new insights into prognostic factors for hepatocellular carcinoma patients in Mongolia, focusing on surgical outcomes and survival.

## Key findings

- Tumor stage II patients had the highest survival rate (46.55%), while stage IIIb had the lowest (1.51%).
- Smaller tumors (≤5 cm) were associated with better survival outcomes.
- Blood loss, vascular invasion, and elevated liver enzymes significantly influenced long-term survival.

## Abstract

Background: Mongolia has a high incidence of hepatocellular carcinoma (HCC), with 85.6 cases per 100,000 population and 70% diagnosed at an advanced stage. HCC accounts for 35% of all cancer-related deaths in the country. The primary treatment for HCC remains hepatotectomy. This study aims to investigate the factors affecting the prognosis of patients undergoing liver resection for HCC in Mongolia. Materials and Methods: A retrospective cohort study was conducted using data from the National Cancer Centre’s eHealth program and cancer registry. The study enrolled 1100 patients who underwent liver resection from 2015 to 2018, with a follow-up period of 5.25–9.25 years to determine survival rates. Results: The study included 980 patients, with a male-to-female ratio of 1.2:1 and an average age of 60 years. Tumour stage II patients had the highest survival rate (46.55%), and those with stage IIIb had the lowest (1.51%) (p = 0.0001). Smaller tumours (≤5 cm) were associated with better survival (p = 0.0006). Histologically, 19.4% had liver cirrhosis, and 80.7% had liver fibrosis. The preoperative median AFP level was 23.9 ng/mL (range 0–121,000 ng/mL). The average survival time post-liver resection was 6.675 years (p = 0.0006). Factors such as blood loss (p = 0.0004), vascular invasion (MaVI-p < 0.0001, MVI p = 0.0011), tumour size ≤ 5 cm (p = 0.0007), and elevated AST and ALT levels significantly influenced long-term survival (p = 0.0004, respectively). Conclusions: The study identified key prognostic factors influencing survival rates in HCC patients post-liver resection. Minimising blood loss, early detection, and managing vascular invasion, along with early-stage detection and treatment, are crucial for improving patient outcomes.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** blood loss (MESH:D016063), Cancer (MESH:D009369), HCC (MESH:D006528), liver cirrhosis (MESH:D008103)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12293281/full.md

---
Source: https://tomesphere.com/paper/PMC12293281